Hager Investment Management Services LLC Sells 365 Shares of Stryker Corporation $SYK

Hager Investment Management Services LLC trimmed its position in shares of Stryker Corporation (NYSE:SYK) by 3.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,075 shares of the medical technology company’s stock after selling 365 shares during the period. Stryker accounts for 2.4% of Hager Investment Management Services LLC’s portfolio, making the stock its 12th largest holding. Hager Investment Management Services LLC’s holdings in Stryker were worth $3,986,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sachetta LLC raised its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the period. Goodman Advisory Group LLC bought a new stake in shares of Stryker during the 1st quarter valued at $32,000. City Holding Co. raised its position in shares of Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 74 shares during the period. Ridgewood Investments LLC raised its position in shares of Stryker by 48.4% during the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares during the period. Finally, Ransom Advisory Ltd bought a new stake in shares of Stryker during the 1st quarter valued at $37,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Up 1.7%

NYSE:SYK opened at $375.35 on Thursday. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market cap of $143.50 billion, a P/E ratio of 49.72, a P/E/G ratio of 2.66 and a beta of 0.94. The firm has a 50-day simple moving average of $380.99 and a 200-day simple moving average of $378.83.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same quarter in the previous year, the business posted $2.81 EPS. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Insider Activity

In other news, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SYK. Needham & Company LLC raised their target price on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Rothschild & Co Redburn began coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price for the company. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Rothschild Redb raised shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, Truist Financial set a $415.00 target price on shares of Stryker and gave the company a “hold” rating in a research note on Monday, August 4th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.